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Abstract
Parathyroid hormone-related protein (PTHrP) possesses a variety of physiological and developmental functions and is also
known to facilitate the progression of many common cancers, notably their skeletal invasion, primarily by increasing bone
resorption. The purpose of this study was to determine whether PTHrP could promote epithelial-to-mesenchymal transition
(EMT), a process implicated in cancer stem cells that is critically involved in cancer invasion and metastasis. EMT was
observed in DU 145 prostate cancer cells stably overexpressing either the 1-141 or 1-173 isoform of PTHrP, where there was
upregulation of Snail and vimentin and downregulation of E-cadherin relative to parental DU 145. By contrast, the opposite
effect was observed in PC-3 prostate cancer cells where high levels of PTHrP were knocked-down via lentiviral siRNA
transduction. Increased tumor progression was observed in PTHrP-overexpressing DU 145 cells while decreased progression
was observed in PTHrP-knockdown PC-3 cells. PTHrP-overexpressing DU 145 formed larger tumors when implanted
orthoptopically into nude mice and in one case resulted in spinal metastasis, an effect not observed among mice injected
with parental DU 145 cells. PTHrP-overexpressing DU 145 cells also caused significant bone destruction when injected into
the tibiae of nude mice, while parental DU 145 cells caused little to no destruction of bone. Together, these results suggest
that PTHrP may work through EMT to promote an aggressive and metastatic phenotype in prostate cancer, a pathway of
importance in cancer stem cells. Thus, continued efforts to elucidate the pathways involved in PTHrP-induced EMT as well as
to develop ways to specifically target PTHrP signaling may lead to more effective therapies for prostate cancer.
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Introduction
Parathyroid hormone-related protein (PTHrP) possesses a
variety of physiological and developmental functions but is also
known to facilitate the progression of many cancers including
prostate cancer. We and others have previously shown that
PTHrP stimulates prostate cancer cell growth, invasion and
metastasis, operating via both paracrine/autocrine and intracrine
pathways [1–3]. PTHrP is known to activate a variety of mitogenic
pathways including MAPK and PI3K/Akt as well as pathways
that stimulate skeletal metastases, one of the most common life-
threatening disorders associated with cancer [4–6].Secreted
PTHrP is known to mediate its cellular effects via interaction
with the G-protein-coupled PTH/PTHrP receptor [7]. Co-
expression of PTHrP and its receptor has previously been
identified in prostate cancer primary tumors and their corre-
sponding bone metastases [8]. Additionally, Freemont et al have
previously reported an increase in expression of PTHrP receptor
in prostate cancer bone metastases compared to primary tumors,
suggesting a potential role of the receptor-mediated pathway in the
formation of skeletal metastases[9].
Epithelial-to-mesenchymal transition (EMT) is a process in
which epithelial cells undergo cytoskeletal and morphological
changes to acquire a mesenchymal phenotype and is important in
normal processes such as fibrosis [10]. Due to its effects on cell
adhesion and mobility EMT is also critically involved in cancer
metastasis and invasion [11,12]. EMT may be characterized by
loss of epithelial markers such as E-cadherin and increased
expression of mesenchymal proteins including vimentin and N-
cadherin [13]. The transcription factors Snail, Slug and Twist are
known to repress E-cadherin expression and induce EMT [14–
16]. Other oncogenic pathways including Src, Ras, Wnt/b-
catenin, PI3K/Akt, MAPK, and TGF-b have all been linked to
EMT [17]. Multiple studies have shown that cancer cells become
more invasive and metastatic after undergoing EMT. In addition,
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EMT has been shown to confer stem cell properties to breast
cancer cells [18].
Given that PTHrP has a role in promoting invasion and
metastasis in prostate cancer and that EMT is one of the main
regulators of these properties in cancer, the crucial question
presented is whether PTHrP is capable of promoting EMT in
cancer cells. PTHrP has been shown to induce EMT in a few
contexts, including during parietal endoderm formation and renal
fibrogenesis [19,20], although the ability of PTHrP to regulate
EMT in cancer has remained uninvestigated. In breast cancer, the
pro-metastatic effects of TGF-b, a potent inducer of EMT, has
been shown to be mediated by PTHrP [21]. Taken together, the
existing literature suggests that regulation of EMT by PTHrP in
cancer is highly likely. In this study we sought to determine the
role of PTHrP in regulating EMT in prostate cancer cells along
with invasion and metastasis. Establishing a role of PTHrP in
regulating bone metastasis cancer and EMT provides both basic
and clinical rationales for elucidating the molecular mechanism of
PTHrP’s actions in many common cancers like prostate.
Materials and Methods
Ethics Statement
The VA IACUC approved this study. All animal experiments
were performed in accordance with the Guidelines for the Care
and Use of Laboratory Animals (NIH Publication Number 85-23)
under assurance number A3873-01. The animals were kept under
isoflurane anesthesia during surgery, and all efforts were made to
minimize suffering. These animals were closely observed, checked
daily and euthanized at the first signs of discomfort. Signs of
discomfort include any abnormal movements, abnormal feeding
or drinking behaviors, lack of self-grooming or any other abnormal
behaviors.
Cells
The DU 145 and PC-3 human prostate cancer cell lines and
were obtained from American Type Culture Collection (Manassas,
VA) and grown in monolayer in RPMI 1640 media (MediaTech,
Herndon, VA) supplemented with 10% fetal bovine serum
(Gemini Bio Products, Woodland, CA) at 37uC in a humidified
incubator with 95% air, 5% CO2. The DU 145 cell line was
selected because it has a low constitutive PTHrP expression and
does not grow or metastasize well in mouse tumor models, in
contrast to PC-3 cells [22–24]. The PC-3 cell line, which was
originally isolated from a prostate adenocarcinoma that had
metastasized to the bone, has an osteolytic phenotype in the
immunocompromised mouse models [22,25].
Plasmid construction
The PTHrP expression plasmids used in this study were human
prepro- PTHrP1–87, PTHrP1-141, and PTHrP1–173; the prepro
forms were used to facilitate PTHrP secretion. The constructs
were directionally subcloned in the pCI-neo expression vector
(Promega, Madison, WI) and the fidelities of all plasmids were
confirmed by DNA sequencing and site-specific PTHrP immuno-
assays [23,26].
PTHrP transfection and lentiviral-mediated silencing
The DU 145 prostate cells were seeded at a density of
26104 cells/cm2 in 12-well cell culture dishes and transfected with
1 mg plasmid per well. Individual G418 resistant colonies (800 mg
G418/ml) were isolated 21–30 days later. The conditioned media
from the picked cell colonies were evaluated for PTHrP expression
by site-specific immunoassays and the PTHrP expressing stable
DU145 cells were expanded [23,26]. It has previously been shown
that wild type and vector-transfected DU 145 exhibit a similar
phenotype [27,28]. Wild type parental DU 145 cells were thus
used as a control for RT-qPCR and matrigel invasion experi-
ments, however parallel experiments were performed with an
empty vector-transfected control derivative. The PC-3 prostate
cells underwent a stable knockdown of PTHrP via lentiviral
siRNA. Control cells were subjected to lentiviral siRNA transduc-
tion with a non-targeting sequence construct.
Quantitative Reverse-Transcription PCR
Cells were harvested two days after being passaged at about 70–
80% confluence. Total cell lysate was collected and RNA was
extracted using an RNeasy kit (Qiagen). cDNA was synthesized
using Superscript III Reverse Transcriptase (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions. Real-time PCR
reaction mixes were prepared using Power SYBR Green (Applied
Biosystems, Foster City, CA), and run on the 7300 Real-time PCR
System (Applied Biosystems) using the following program: 95uC
for 10 min, 95uC for 30 s, and 60uC for 1 min, for 40 cycles.
Results were analyzed using the Comparative ddCt method and
melting curves were performed to ensure product specificity.
Experiments were done in technical triplicates and were repeated
at least twice independently. GAPDH gene expression was
measured as endogenous control. Primers were custom ordered
(Eurofins MWG Operon, Huntsville, AL) using the following
sequences:
Snail Forward 59-TCTGAGTGGGTCTGGAGGTG-39, Snail
Reverse 59- CTCTAGGCCCTGGCTGCTAC-39, GAPDH For-
ward 59-CTTCGCTCTCTGCTCCTCC -39, GAPDH Reverse
59-CAATACGACCAAATCCGTTG -39, E-cadherin Forward
59-GGCGGAGAAGAGGACCAGGACT-39, E-cadherin Re-
verse 59-TGGCAGGGCGGGGAAGATACC-39, Vimentin For-
ward 59- GGAAATGGCTCGTCACCTTCGT-39, Vimentin
Reverse 59-AGAAATCCTGCTCTCCTCGCCT-39.
Immunofluorescence
Cells were trypsinized and cultured on cover slips. The cells
were fixed with 4% paraformaldehyde and blocked in goat serum
in Dulbecco’s phosphate buffered saline at room temperature prior
to incubation with mouse monoclonal to anti-human vimentin
(Sigma Aldrich, St. Louis, MO). Cells were then incubated with a
goat anti-mouse FITC conjugated secondary antibody (Chemicon,
Temecula, CA) and counterstained with DAPI. Finally, SlowFade
Gold antifade reagent (Invitrogen, Carlsbad, CA) was used to
mount the cover slips onto slides. Fluorescent images were
obtained at 40X using Leica DMIRE2 inverted fluorescence
microscope and computer program Simple PCI was used for
image capture.
Matrigel Invasion Assay
Invasion of PC3 and DU 145 cells was measured using a
Matrigel invasion assay (Becton Dickinson, Bedford, MA).
Transwell inserts of 8 mm pore size were coated with a final
concentration of 1 mg/mL of Matrigel in cold serum-free
DMEM. Cells were trypsinized, and 500 mL of cell suspension
(16105 cells/mL) were added in triplicate wells. The lower
chamber of the transwell was filled with 750 ml of culture media
containing 0.5% serum as a chemoattractant and allowed to
incubate at 37uC for 48 hours. Invading cells on the lower surface
that passed through the filter were fixed and stained using crystal
violet in gluteraldehyde and photographed. The number of the
stained nuclei was counted in a predetermined and consistent
section of each well.
PTHrP Promotes Prostate Cancer EMT
PLOS ONE | www.plosone.org 2 January 2014 | Volume 9 | Issue 1 | e85803
Animals
Six-month-old male, severe combined immunodeficiency
(SCID) mice were housed in a barrier filter room and fed Purina
rodent chow ad lib. The animals were bled at the end of the study
using a retro-orbital method.
Orthotopic Tumor Implantation
Subconfluent DU145 and stably transfected DU145-PTHrP(1-
173)-GFP cells were freshly trypsinized, counted, and placed on ice
immediately before injection. The mice were injected with 106
cells subcutaneous space of the flank of the animal in a total
volume of 0.25 ml serum free RPMI 1640 media. The mice were
sacrificed to harvest tumor tissue 4 weeks after tumor cell
injections. Tumor fragments (1 mm3) were freshly prepared from
the subcutaneous tumors and implanted into the prostate lateral
lobe of another SCID mouse (22–24). The 1 mm3 tumor
fragments were dissected, measured with calipers, and weighed
to assure the exact amount of starting tumor was used for each
animal. The prostate capsule was exposed following a lower mid-
line abdominal incision and a tumor fragment was inserted into
the capsule. The prostate capsule was then closed with an 8-0
surgical suture and the incision in the abdominal wall was closed
with a 6-0 surgical suture in one layer [29].
The animals were kept under isoflurane anesthesia during
surgery. All procedures of the operation described above were
performed with a 7 X magnification microscope. The mice were
evaluated 60 days after the tumor implantation for tumor
progression and metastasis by fluorometry and for skeletal
abnormalities by X-ray. High-magnification imaging of the
GFP-expressing tumors was carried out with a Leica fluorescent
stereomicroscope, model LZ12, equipped with a 50 W mercury
lamp and whole-body imaging was carried out in a light box
illuminated by blue light fiber optics (Lightools Research,
Encinitas, CA) and imaged using a thermoelectrically cooled
color CCD camera (Hamamatsu Photonics, Bridgewater, NJ).
Intraosseous Injections
To evaluate the effect of PTHrP on prostate cancer growth in
bone, we used an intra-tibial model for prostate cancer bone
metastasis (1, 24). We studied five types of stably transfected GFP
expressing DU145 cells: (1) wild-type, (2) vector (pCI-neo), (3)
PTHrP(1–87), (4) PTHrP(1–141) and (5) PTHrP(1–173) trans-
formed cells. The mice were injected with 106 cells in 15 ml sterile
PBS into the bone marrow of the right proximal tibia using a 26-
gauge needle and a Hamilton glass syringe. The left tibia served as
the negative control. The mice were evaluated 60 days after the
intraosseous injections for skeletal abnormalities by X-ray [24].
Skeletal X-rays were exposed with 40 keV for 20 seconds in a
Faxitron 5000 series X-ray cabinet and Kodak X-Omat TL films
were processed in a Kodak film processor. For higher resolution
imaging of the bone abnormalities, we used a GE eXplore Micro
CT (GE Healthcare).
PTHrP Immunoassay
Cell extracts and media PTHrP were measured by RIA based
on PTHrP(1–34), PTHrP(38–64), and PTHrP(109–141), as
described previously [30]. All of the samples were assayed in
multiple dilutions and in triplicates.
Statistical Analysis
All experiments were performed in triplicate and error bars
represent standard deviation. Statistical significance was tested
using a two sample independent t-test (2-tailed test) with the
threshold set at P,0.05.
Results
PTHrP Overexpression Promotes the Expression of
Mesenchymal Markers
To study regulation of EMT, PTHrP was stably overexpressed
in DU 145, a prostate cancer cell line with low basal PTHrP
expression as determined by immunoassay (Figure 1A). Two
clones were created, with one overexpressing the 1–141 isoform of
PTHrP and the other overexpressing the 1–173 isoform
(Figure 1B). Both clones displayed markers of EMT, expressing
notably higher levels of the mesenchymal proteins snail and
vimentin and lower levels of E-cadherin relative to parental DU
145, as determined by qRT-PCR (Figure 1B). Upon stable
overexpression of full-length PTHrP-(1–173) in DU 145, vimentin
and snail mRNA expression were elevated by 115 and 6.82 fold,
respectively, while E-cadherin expression decreased demonstrably
by 2080 fold. Similarly, stable overexpression of PTHrP-(1–141)
increased vimentin and snail mRNA expression by 23.5 and 3.88
fold, respectively, and decreased E-cadherin expression by 12.3
fold. Data is shown with the wild-type parental derivative as a
control. In a parallel experiment, PTHrP-overexpressing DU 145
cells demonstrated a 6.06 fold induction of snail and 9.68 decrease
in E-cadherin expression as compared to the empty vector-
transfected DU 145 derivative (data not shown). The induction of
EMT is verified by an immunofluorescence assay. Overexpres-
sions of both isoforms of PTHrP demonstrate a decrease in E-
cadherin with an increase in vimentin protein expression
(Figure 1C).
PTHrP Knockdown Reduces Expression of Mesenchymal
Markers
To further demonstrate the regulation of EMT by PTHrP in
prostate cancer, permanent PTHrP knockdown via retroviral
transduction was performed in PC-3, a prostate cancer cell line
with high basal PTHrP expression as determined by immunoassay
(Figure 2A). In PC-3-KD cells, expression of PTHrP was reduced
to 15% of the control PC-3 (Figure 2B), while levels of Snail and
vimentin were down-regulated by 3.03 and 3.73 fold, respectively,
and E-cadherin expression was elevated by 2.30 fold (Figure 2B).
The change in EMT protein expression is demonstrated with an
immunofluorescence assay. Knocking down PTHrP downregu-
lates vimentin and upregulates E-cadherin, which confirms the
qPCR data (Figure 2C). Together with Figure 1, these data suggest
that PTHrP activity or expression promotes EMT in prostate
cancer.
PTHrP Regulates Invasion and Upregulation of MMP-9
In order to establish that activation of PTHrP or EMT results in
increased invasiveness in our experimental system, a matrigel
invasion assay was performed to determine the relative invasive-
ness of DU 145-PTHrP(1–141), DU 145-PTHrP(1–173), and PC-
3-KD cells compared to their respective controls. DU 145-
PTHrP(1–141) and DU 145-PTHrP(1–173) cells were found to be
3.0 (p,.01) and 2.9 (p,.05) times more invasive than parental DU
145 cells, respectively (Figure 3A). Meanwhile, PC-3-KD cells
were found to be only 0.5 times (p,.01) as invasive as parental
PC-3 cells (Figure 3B). In a parallel experiment, PTHrP-(1–141)
and -(1–173) DU 145 cells demonstrated a 2.0 (p,0.5) and 2.1
fold (p,.05) increase in matrigel invasion as compared to the
empty vector-transfected DU 145 derivative, respectively (data not
shown). Lastly, PTHrP overexpression in DU 145 was observed to
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Figure 1. PTHrP overexpression induces EMT. A) Quantification of PTHrP protein levels in control and PTHrP-overexpressing DU 145 cells by
immunoassay. B) mRNA expression of PTHrP and EMT markers in control and PTHrP-overexpressing DU 145 cells. C) Immunofluorescence images
confirming the overexpression of PTHrP, the upregulation of vimentin, and downregulation of E-cadherin in PTHrP-overexpressing DU 145 cells.
doi:10.1371/journal.pone.0085803.g001
Figure 2. PTHrP Knockdown reverses EMT. A) Quantification of PTHrP protein levels in control and PTHrP-knockdown PC-3 cells by
immunoassay. B) mRNA expression of PTHrP and EMT markers in control and PTHrP-knockdown PC-3 cells. C) Immunofluorescence images
confirming the overexpression of PTHrP the upregulation of vimentin, and downregulation of E-cadherin in control and PTHrP-knockdown PC-3 cells.
doi:10.1371/journal.pone.0085803.g002
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upregulate the expression of MMP-9 by 17.1 and 7.10 fold in
PTHrP-(1–141) and PTHrP-(1–173) expressing derivatives, re-
spectively, while knockdown in PC-3 downregulated MMP-9 by
25.1 fold (Figure 3C).
PTHrP Promotes Tumor Growth and Bone Destruction in
an Orthotopic/Intraosseous Mouse Model
DU 145 and DU 145-PTHrP(1–173) cells were stably
transfected with a GFP expression plasmid and implanted
orthotopically into the prostate bed of nude mice or directly into
bone, as previously described (1). Although all mice formed
tumors, those implanted with DU 145-PTHrP(1–173) cells formed
significantly larger tumors compared to those injected with normal
DU 145 cells. Representative images show extensive tumor mass
in mice injected with DU 145-PTHrP(1–173) cells compared to
mice injected with parental DU 145 (Figure 4A). In addition,
metastasis to the spine was observed in one of the mice injected
with DU 145-PTHrP(1–173), while no mice injected with DU 145
formed metastases (Figure 4B). DU 145 or DU 145-vector cells
formed no tumor when injected into mice tibiae while DU 145-
PTHrP(1–141) or DU 145-PTHrP(1–173) cells injected into mice
tibiae resulted in tumor formation, invasion and destruction of
bone (Figure 5), confirming the well established role of PTHrP in
bone resorption. Lastly, expression of PTHrP in tumors were
confirmed by immunohistochemistry (Figure 5B).
Discussion
We have identified PTHrP not only as a critical mediator of
tumor progression in prostate cancer, but also as a promoter of
EMT. While PTHrP has been shown to induce EMT in
development [10,31], our observation that it promotes EMT in
cancer as well remains a novel finding. This finding implies that
PTHrP may have an even more significant role in cancer
progression than previously believed, since the ability to regulate
EMT implies the potential to regulate a variety of properties
related to cancer progression including invasion, metastasis, cell-
motility, cell-adhesion, angiogenesis, and stemness/tumorigenicity
[11,18,32–34]. Prognosis for advanced prostate cancer remains
poor due to frequent bone metastasis and invasion [35,36]. Thus,
targeting of PTHrP may lead to more effective therapies for
prostate cancer.
Our data showed that PTHrP overexpression in DU 145 cells
induced EMT and promoted invasion, tumorigenicity, and
metastasis, while PTHrP knockdown in PC-3 cells induced
contrary effects. Furthermore we observed that the PC-3 cell line
has high basal expression of PTHrP as determined by PTHrP
immunoassay and is inherently more metastatic and invasive
compared to DU 145, which has low basal PTHrP expression.
These observations posit that PTHrP may not only facilitate
Figure 3. PTHrP Promotes Invasion and MMP-9 Expression. A)
Matrigel invasion assay showing increase in invasion of DU145 cells
upon overexpression of either PTHrP 1–141 or 1–173. B) Matrigel
invasion assay showing decrease in invasion of PC3 cells upon
knockdown of PTHrP. C) mRNA levels of MMP-9 in PTHrP-overexpress-
ing DU145 cells and PTHrP-knockdown PC3 cells relative to their
respective controls. * indicates p,.05, ** indicates p,.01.
doi:10.1371/journal.pone.0085803.g003
Figure 4. PTHrP Promotes Tumorigenesis in Orthotopic Mouse
Model. A) Orthotopic mouse model showing a mouse injected with
DU145-GFP cells. B) Mouse injected with DU 145-PTHrP(1–173) cells. C)
Evidence of bone destruction in mouse injected with DU 145-PTHrP(1–
173) cells. D) Spine metastasis in a mouse injected with DU 145-
PTHrP(1–173) cells.
doi:10.1371/journal.pone.0085803.g004
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metastasis by promoting bone resorption, but may also be an
important regulator of aggressive phenotype in prostate cancer.
Both 1–141 and 1–173 isoforms of PTHrP were found to promote
EMT, consistent with the fact that the classical active site is located
near the amino-terminus as shown by previous studies [37];
however, additional processed peptides of PTHrP may also be
important mediators of this action. Targeting all isoforms of
PTHrP for anti-cancer therapy may necessary, although targeting
of the 1–141 isoform may be of primary importance as it accounts
for the majority of PTHrP expression in humans.
Downstream targets that are activated by PTHrP include Snail,
AP-1, CREB, ERK1/2, VEGF, PI3K/Akt and Cyclin D1 [20,38–
45]. Snail promotes EMT through direct transcriptional repression
of E-cadherin [15]. CREB upregulates VEGF which in turn
promotes EMT, invasion and angiogenesis [46,47]. The PI3K/
Akt pathway is a key regulator of cell proliferation and has also
been shown to induce EMT in a variety of cancers [48]. AP-1 was
shown to be involved in TGF-b-induced EMT [49]. Overexpres-
sion of cyclin D1 has been shown to induce glioma invasion by
increasing metalloproteinase activity and cell motility [50].
Prevailing studies show that PTHrP, TGF-b, EGF, and VEGF
cooperate through activation of ERK1/2 to induce EMT during
renal fibrogenesis [19], and that Snail is an immediate early target
of PTHrP in murine parietal endoderm formation [20]. One or a
combination of these pathways is likely to explain the induction of
EMT and invasion that were observed in our experiments, in
which we confirmed the induction of Snail by PTHrP. Though it
has been shown previously that PTHrP is able to upregulate Snail
transcription in the absence of de novo protein synthesis [20], it
remains unclear whether this effect is through direct binding to the
Snail promoter or through activation of signaling pathways such as
Akt that are known to regulate Snail. Either way, further studies
would be needed to confirm the mechanism of PTHrP-induced
EMT in prostate cancer.
It is possible that various other pathways rely on PTHrP to
promote EMT, invasion and metastasis. TGF-b, a potent inducer
of EMT, has been shown in breast cancer to promote PTHrP
expression resulting in bone destruction [21]. Various oncopro-
teins including Ras, Tpr-Met, Src have all been shown to target
PTHrP and also have proven roles in EMT, invasion and
metastasis [51–53]. Of particular interest would be Indian
hedgehog, which is known to regulate PTHrP during early bone
and cartilage growth [54,55]. Members of the hedgehog family are
aberrantly activated in a variety of cancers including prostate
cancer, have been shown to indirectly promote EMT, and are
theorized to have a role in the transformation of adult stem cells
into cancer stem cells [56–59]. It would be interesting to determine
whether Ihh relies on PTHrP for induction of EMT and other
malignant properties in cancer.
Ongoing research continues to reinforce the theory that cancer
stem cells are the main drivers of cancer progression and key
determinants of therapeutic response [60]. Thus, an important
question to consider is whether PTHrP may regulate prostate
cancer stem cells through an EMT-mediated pathway. As EMT
has been shown previously to induce cancer stem cell properties
[18], it follows that PTHrP should potentially be able to regulate
stem cell properties in prostate cancer and thus may be a valuable
therapeutic target for preventing recurrence and metastasis.
Prostate cancer stem cells have previously been isolated and
characterized by a CD44+/CD133+/a2b1hi phenotype [61].
Future work must focus on the ability of PTHrP to regulate this
compartment in prostate cancer.
The finding that PTHrP induces EMT while promoting
invasion and tumor growth suggests that treatments that target
PTHrP may be used in conjunction with conventional treatments
for inhibiting invasion and metastasis in prostate cancer, especially
for recurrent tumors. We have previously screened a library of
compounds and identified several that are capable of inhibiting
PTHrP expression and cell growth in lung cancer [62]. It would be
of great clinical interest to extend these results to prostate cancer
and to determine whether such drugs are also capable of blocking
PTHrP-induced EMT and invasion. Meanwhile, further efforts to
characterize the pathways involved in PTHrP-induced EMT may
lead to the elucidation of a role for PTHrP in cancer stem cell
development and to novel therapies that could significantly
improve the prognosis of metastatic prostate cancer (1, 57).
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